Hot Longevity Mandate: US-Based Subsidiary of a Big Pharma Company

1 Feb

The firm is a developer of gene therapy treatments founded in 2013 and is a headquartered in the US. The firm is a wholly owned subsidiary of a large pharma. The company has an integrated gene therapy platform for developing medicines in these core areas: ophthalmology, hematology, immunology, and CNS/neurodegenerative disease. Currently, the firm is actively seeking early-stage opportunities that fit their strategic interests for early-stage partnering, in-licensing, and more. The firm seeks opportunities globally.

The firm is interested in innovative therapeutics that can supplement their pipeline in the aforementioned therapeutic/disease areas. The firm’s strongest interests lie in gene therapies, but the firm is also interested in biologics they can utilize in adeno-associated viral (AAV) vectors that have been engineered in-house through the firm’s proprietary platform to enable efficient therapeutic delivery. In terms of stage of development, the firm is interested in evaluating opportunities from the earliest stages, from lead optimization and beyond. The firm is not interested in technologies that fall in other life science sectors, including medical devices, diagnostics, and digital health.

The firm seeks to be a flexible partner with opportunities they engage in, and have no strict requirements for the company or management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: